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Resistance to single or multiple chemotherapeutic drugs is a major complication in clinical oncology and
is one of the most common treatment limitations in patients with reoccurring cancers. Nanoparticle
(NP)-based drug delivery systems (DDS’s) have been shown to overcome drug resistance in cancer cells
mainly by avoiding the activation of efﬂux pumps in these cells. We demonstrate in this work that
polyester-based hyperbranched dendritic-linear (HBDL)-based NPs carrying doxorubicin (Dox) can
effectively overcome microsomal glutathione transferase 1 (MGST1)-mediated drug resistance in breast
cancer cells. Our DDS was much more effective at considerably lower intracellular Dox concentrations
(IC50 6.3 mM vs. 36.3 mM) and achieved signiﬁcantly greater reductions in viability and induced higher
degrees of apoptosis (31% vs. 14%) compared to the free drug in the resistant cells. Dox-loaded HBDL NPs
were found to translocate across the membranes of resistant cells via active endocytic pathways and to
be transported to lysosomes, mitochondria, and the endoplasmic reticulum. A signiﬁcantly lower amount
of Dox accumulated in these cytoplasmic compartments in resistant cells treated with free Dox. More-
over, we found that Dox-HBDL signiﬁcantly decreased the expression of MGST1 and enhanced
mitochondria-mediated apoptotic cell death compared to free Dox. Dox-HBDL also markedly activated
the JNK pathway that contributes to the apoptosis of drug-resistant cells. These results suggest that HBDL
NPs can modulate subcellular drug distribution by speciﬁc endocytic and trafﬁcking pathways and that
this results in drug delivery that alters enzyme levels and cellular signaling pathways and, most
importantly, increases the induction of apoptosis. Our ﬁndings suggest that by exploiting the cell
transport machinery we can optimize the polymeric vehicles for controlled drug release to overcome
drug resistance combat drug resistance with much higher efﬁcacy.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.1. Introduction
Chemotherapy is the most common anticancer therapy, after
surgical resection, currently employed in the clinical management
of cancer. Modern chemotherapeutic therapy has been a success
story with increased survivability and positive therapeutic results
for many of the most common cancers, including breast cancer [1].nsferase 1; Dox, doxorubicin;
encapsulating doxorubicin;
röm).
r Ltd. Open access under CC BY-NC-SAHowever, antitumor efﬁcacy can be severely limited by the devel-
opment of multi-drug resistance in cancer cells. Some cancer cells
have intrinsic resistance before drug treatment while others
develop resistance during the course of chemotherapy [2,3]. This
acquired resistance frequently involves cross-resistance to other
drugs and is known as multi-drug resistance [4]. Drug resistance is
correlated with a variety of biochemical changes, including
increased efﬂux of the cytotoxic drugs due to overexpression of the
ATP-binding cassette transporters, DNA repair activation, and
altered levels of apoptosis [5,6]. Enzymatic detoxiﬁcation of cyto-
static drugs also constitutes a major mechanism of tumor drug
resistance [6], and it has been clearly shown that overexpression of
the glutathione transferases (GSTs) in tumors are linked to the
development of multi-drug resistance [7e9].
One important strategy for overcoming drug resistance is to
restore drug sensitivity through the use of nanoscale DDS’s [10,11] license.
X. Zeng et al. / Biomaterials 35 (2014) 1227e12391228and liposomal [12e15] and/or polymer-based nanomedicines in
particular [16e18]. Kabanov et al. have shown that Pluronic block
copolymer micellar types of carriers can avoid permeability
glycoprotein (Pgp) activation in response to doxorubicin (Dox)
treatment both in vitro and in vivo [19e21]. Other types of nano-
medicines include poly(lactic-co-glycolic acid) (PLGA) NPs [22],
poly(N-(2-hydroxypropyl)methacrylamide) (poly(HPMA))-Dox
conjugates [23], and iron oxide based NPs [24] among several
others. Another type of polymer-based NP that has been explored
for DDS applications is dendrimers [25e28]. Dendrimers are highly
branched single molecule entities that are being used either as
single entities or as linear-dendritic hybrid materials [25e28].
Polyester-based dendritic materials [29], and especially aliphatic
polyesters based on poly 2,2-bis (methylol) propionic acid (bis-
MPA) building blocks exhibit promising characteristics for utiliza-
tion as a polymer-based nanoscale DDS [30e35]. Bis-MPAmaterials
have been shown to be non-toxic, non-immunogenic, and biode-
gradable in several publications as well as highly efﬁcient in vivo
DDS systems.
Inspired by the work described by Frechét et al. who used bis-
MPAebased bow-tie dendron structures that exhibited unsur-
passed results in vivo [25,32e34], our group previously developed
hyperbranched dendritic-linear (HBDL)-based NPs made from
poly(ethylene glycol) (PEG)-grafted from Boltorn [36,37].
Hyperbranched polymers offer the high functionality seen with
dendrimers. They are less well deﬁned, but they are signiﬁcantly
easier to synthesize on a large scale and can be used to construct
complex nanoparticle assemblies [30,31]. In our previous work,
the anti-neoplastic drug Dox was successfully encapsulated within
the HBDL NP assemblies, and the Dox-loaded NPs improved the
antiproliferative efﬁcacy of the drug over the non-formulated
version of Dox in vitro [36,37]. In addition, our previous work
demonstrated that breast cancer cells could efﬁciently take up the
NPs via both macropinocytosis and clathrin-dependent endocy-
tosis [36].
Based on the results of our previous studies, we hypothesized
that the nanostructures might modulate the delivery of Dox to
reverse drug resistance in breast cancer cells. Understanding the
mechanismsofhowtheNPs interactwithdrug-resistant cancer cells
would help lead to the improved design of NP-based DDS’s as efﬁ-
cient and safe carriers for overcoming cancer drug resistance. In this
study, we used the genetically engineered MCF-7/ADR cell line as a
drug-resistant cell model that overexpresses microsomal gluta-
thione transferase 1 (MGST1). MGST1 is up regulated in many
different malignant tissues compared to normal tissues and has
been linked to multidrug resistance, including resistance to Dox
[38]. In this work, we have expanded the use of our DDS to the
treatment of drug-resistant breast cancer cells and investigated the
anti-proliferative effects, uptake proﬁles, endocytosis mechanisms,
and subcellular drug delivery of this formulation as well as the
altered cellular functions indrug-resistant cells.We showadramatic
reversal of the resistance to Dox, a signiﬁcant reduction in cell
viability, and an increase in apoptosis in the drug-resistant cellswith
our polyester-based nanomedicine system. Overcoming GST-
mediated resistance represents a viable target for improving the
chemotherapeutic treatment of drug-resistant cancers in the future.
2. Materials and methods
2.1. Preparation of HBDL, Dox-HBDL, and HBDL-FL nanoparticles
The Boltorn H30-based hyperbranched dendritic-linear (HBDL) copolymers
and ﬂuorescein cadaverine-labeled (HBDL-FL) conjugates were synthesized and
characterized as previously reported by our group [36,37]. In brief, the hyper-
branched dendritic-linear (HBDL) polymers formmicellar assemblies in the aqueous
solutions due to its amphiphilic nature. The hydrophilic PEG segments served as a
shell stabilizing themicelles, whereas H30 Boltorn constitutes the hydrophobic core.
The micelles have on average 5 PEG chains (10 kDa) per hyperbranched coremolecule. BoltornH30-(PEG10k): MnNMR w 53,300 Da, MwGPC ¼ 14,000 Da
(polystyrene equivalent), Mn GPC ¼ 11,400 Da (polystyrene equivalent), Mw/
Mn ¼ 1.2.
The preparation of drug loaded Dox-HBDL nanoparticles was performed by
employing similar methods as described earlier [37], and the formulation was
measured by dynamic light scattering (DLS, Nano-ZS, Malvern).
Diameter ¼ 316 nm  158 nm (Z-average). Zeta potential ¼ 1.8 mV  0.4 mV. The
concentration of Dox and entrapment efﬁciency was assessed to be 0.097 mM and
30.6%, respectively, by UV spectrophotometry.
2.2. Cells and chemicals
The human breast carcinoma cell lineMCF-7 with low endogenous expression of
MGST1 was purchased from the American Type Culture Collection (ATCC; Manassas,
VA) and maintained in Dulbecco’s Modiﬁed Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum, 100 units/mL penicillin, and 100 mg/mL streptomycin
under 5% CO2 at 37 C. MCF-7/ADR cells with overexpression of MGST1 were
transfected with a vector containing rat MGST1 as described previously [39], and the
cells were cultured in the DMEM medium supplemented with 1 mg/mL geneticin.
MCF-7 cells are used as controls as no signiﬁcant difference between these and
antisense transfected MCF-7 was observed.
DAPI, Cholera toxin B subunit (CTB) Alexa 647, transferrin Alexa 647, lysosensor,
ERtracker, Mitotracker, CellROX reagent, MitoSOX reagent, Thiol reagent, Bodipy
probe, MitoDiIC kit, JNK1&2(pTpY183/185), and secondary antibodies were obtained
from Invitrogen (Eugene, OR). Speciﬁc antibodies against the early endosome
marker (EEA1) and the Golgi marker (TGN46) were purchased from Abcam Inc. The
polyclonal rabbit IgG against rat MGST1 was generated by the laboratory of Prof Ralf
Morgenstern. Dextran-rhodamine was prepared by Jakob Regberg as previously
described [36]. Water, dimethyl sulfoxide (DMSO), methanol, (3-(4,5-
dimethylthiazol-2-yl))-2,5-diphenyl tetrazolium bromide (MTT), and other HPLC-
grade solvents were from SigmaeAldrich Company, Ltd. All pharmacological in-
hibitors and other reagents of general laboratory grade were purchased from Sigma
(St. Louis, MO) unless otherwise stated. Stock solutions were prepared and stored
at 80 C in small aliquots as per manufacturer’s recommendation.
2.3. Cytotoxicity studies
The level of MGST1 expression in MCF-7 andMCF-7/ADR cells was conﬁrmed by
immunostaining and confocal ﬂuorescencemicroscopy. MCF-7 andMCF-7/ADR cells
were seeded at 5  104 cells per well in a 96-well plate, pre-incubated for 24 h, then
incubated with free Dox or Dox-HBDL for 48 h at Dox concentrations ranging from
0.001 mM to 10 mM. Untreated cells in medium were used as controls. The MTT assay
was used to measure cytotoxicity [37]. All experiments were carried out with three
replicates. The cytotoxicity of empty HBDL NPs was tested with the method above,
but the concentration of empty micelles ranged from 50 mg/mL to 500 mg/mL.
2.4. Cellular uptake of Dox-HBDL
MCF-7 and MCF-7/ADR cells were seeded onto 6-well culture plates (1  105
cells per well) and incubated for 24 h. The cells were treated with 1 mM Dox or Dox-
HBDL (1.0 mM Dox-equivalent) for 1, 3, 6, 12, or 24 h. The cells were then washed
three times with PBS, trypsinized, and transferred to tubes and centrifuged. The
pellets were re-suspended in 0.5 mL of PBS for immediate analysis by ﬂow cytom-
etry. Flow cytometry was performed on a FACS Calibur ﬂow cytometer (Becton
Dickinson, San Jose, CA). Data from 1  104 cells were collected and analyzed using
the CellQuest software (Becton Dickinson). The cellular uptake of Dox and Dox-HBDL
was further conﬁrmed by confocal laser scanning microscopy (CLSM, Olympus
FV1000). Cells grown on coverslips in a 6-well tissue culture plate were cultured
with Dox and Dox-HBDL NPs at a concentration of 1 mM. After incubation for 24 h, the
cells were washed with PBS and ﬁxed with 5% paraformaldehyde in PBS. Canadian
Balsam was dropped on the slides to seal the cell samples after the cells were
washed with PBS. The stained coverslips were imaged using CLSM.
2.5. Uptake mechanism studies
To study the endocytic pathways of the nanoparticles, MCF-7 and MCF-7/ADR
cells were seeded as described above in 12-well plates. Cells were treated with
1 mM Dox or Dox-HBDL (1.0 mM Dox-equivalent) inmedium and incubated for 3 h. Co-
localization assays in living cells were performed to identify the endocytic vesicles
involved in the nanoparticle internalization. Following the nanoparticle treatment,
the cells were incubated with different dyes depending on the purpose of the
staining: dextranerhodamine conjugate to label macropinosomes, transferrin Alexa
647 conjugate to label clathrin, and CTB Alexa 647 conjugate to label caveolin. Cells
were imaged with CLSM. In the endocytic inhibition assays, cells were washed with
warm (37 C) PBS, and fresh medium was added containing the inhibitors of
endocytic pathways 0.5 h prior to the addition of the Dox-HBDL suspensions. Next,
the cells were treated with Dox-HBDL (1.0 mM Dox-equivalent) either in the presence
or absence of the endocytosis inhibitors. Various well-characterized inhibiting drugs
(ﬁlipin, nystatin, phenylarsine oxide, chlorpromazine, amiloride-HCl, and cytocha-
lasin D) were selected for their ability to inhibit speciﬁc steps in the endocytic
pathway, and the effects of low temperature (4 C) on nanoparticle uptakewere also
Fig. 1. Expression of MGST1 in cells and the cytotoxicity of doxorubicin (Dox). (A) Detection of the MGST1 expression in MCF-7/ADR cells or MCF-7 cells by confocal microscopy.
Scale bar ¼ 20 mm. Cytotoxicity of free Dox and Dox-HBDL NPs to (B) MCF-7 cells and (C) MCF-7/ADR cells as assessed by an MTT assay.
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37 C, 1 mM of Dox and the Dox-HBDL nanoparticle (1.0 mM Dox-equivalent) solution
was added to the cells for 3 h after which the cells were prepared for FACS analysis as
described above.
2.6. Intracellular localization study
To study the subcellular localization of Dox, MCF-7 and MCF-7/ADR cells were
seeded and treated as described above in 12-well plates. Immunostaining was usedto investigate intracellular drug localization. After 6 h incubation of Dox and Dox-
HBDL NPs at a 5.0 mM Dox equivalent concentration, cells were ﬁxed with 4% para-
formaldehyde and labeled with speciﬁc antibodies for early endosomes (EEA1) or
the Golgi network (TGN). Drug co-localization assays with Lysosensor, Mitotracker,
and ERtracker were performed to label lysosomes, mitochondria, and endoplasmic
reticulum, respectively. Overlap between drug and the FL-labeled HBDL carrier
localization was also studied by incubation of Dox-encapsulated micelles in MCF-7/
ADR cells. Cells were imaged using CLSM, and the Olympus FV10-ASW and ImageJ
100
MCF-7
MCF-7/ADR
Control
Dox-HBDL
Free Dox
Control
Dox-HBDL
Free Dox
C
o
u
n
t
s
80
60
40
20
0
30
25
I
n
t
e
n
s
i
t
y
 
(
%
)
Distance (µm)
20
15
10
5
0
30
25
I
n
t
e
n
s
i
t
y
 
(
%
)
20
15
10
5
0
80
70
60
50
I
n
t
e
n
s
i
t
y
 
(
%
)
40
30
20
10
0
0 5 10 15 20 25 30 35
Distance (µm)
0 5 10 15 20 25 30 35
30
25
I
n
t
e
n
s
i
t
y
 
(
%
)
20
15
10
5
0
Distance (µm)
0 5 10 15 20 25 30 35
Distance (µm)
0 5 10 15 20 25 30 35
10
0
10
1
Fluorescence intensity
10
2
10
3
10
4
10
0
10
1
Fluorescence intensity
10
2
10
3
10
4
100
C
o
u
n
t
s
80
60
40
20
0
Fig. 2. Cellular uptake of (A) free Dox and (B) Dox-HBDL NPs by MCF-7 and MCF-7/ADR cells. The concentration of Dox (free Dox and equivalent Dox in micelle form) in the cell culture was 1 mM. Flow cytometry was used to quantify the
uptake of free Dox or Dox-HBDL NPs by the cells. Three independent experiments were performed. (C) Representative dot plots showing ﬂuorescence channel analysis and (D) quantitative comparison of Dox accumulation in MCF-7
cells and MCF-7/ADR cells after incubation with free Dox or Dox-HBDL NPs for 24 h. (E) Confocal laser scanning microscopy images of cells treated with free Dox or Dox-HBDL NPs at 1 mM for 24 h. Nuclei are stained with DAPI (blue), and
Dox is indicated by red ﬂuorescence. Scale bar ¼ 20 mm. The line-scanning proﬁles of ﬂuorescence intensity of the cells are indicated by arrows. The blue line represents the intensity from DAPI and the red line represents the intensity
from Dox. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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topographic proﬁles.
2.7. Assessment of MGST1 expression, lipid peroxidation, and mitochondrial
membrane potential
MCF-7 cells and MCF-7/ADR cells were plated in 6-well plates at a density of
1 105 cells per well and incubated at 37 C in a 5% CO2 humidiﬁed atmosphere for
24 h. Cells were incubated with either free Dox or Dox-HBDL at a concentration of
5 mM for 24 h at 37 C. After 24 h incubation, cells were collected, centrifuged at
5000 rpm for 5 min to pellet the cells, and washed with PBS. After incubation with
the MGST1 antibody and washing, the cells were further incubated with the Alexa
647-labeled secondary antibody at room temperature. The cells were then washed
and the MGST1 level was determined using the ﬂow cytometer. To determine the
intracellular lipid peroxidation and mitochondrial membrane potential, cells were
treated with free Dox and Dox-HBDL using the same protocol described above.
According to the manufacturer’s protocol, cells were collected then resuspended in
PBS with 50 nM MitoDiIC (for assessment of mitochondrial membrane potential,
Djm) or 5 mM C11-Bodipy581/591 (a marker of lipid peroxidation) and incubated at
room temperature for 30 min. After washing with PBS, the cell samples were sub-
jected to ﬂow cytometer analysis.
2.8. Measurement of GSH, mitochondrial superoxide, and cellular ROS
Intracellular GSH, ROS, and mitochondrial superoxide levels were measured by
assays as previously described [40]. Cells were exposed to free Dox (5 mM) and Dox-
HBDL nanoparticles (5.0 mM Dox-equivalent) for 24 h. The following ﬂuorescent
probes were incubated with cells at 37 C in the dark prior to harvest: (i) 20 mM
Thioltracker dye (a marker of glutathione, GSH) for 30 min, (ii) 5 mM MitoSOX for
10 min (for assessment of mitochondria-generated superoxide), or (iii) 5 mM CellROX
reagent for 30 min (for assessment of cellular ROS production). Cells were washed
and the protein concentration was measured with the BCA protein assay (Sigma).
Fluorescence of cell samples was measured using a spectroﬂuorimeter (BioTek
Synergy MX, VT) according to the manufacturer’s protocol, and ﬂuorescence in-
tensity was compared with equal amounts of protein.
2.9. Cell apoptosis and JNK activation analysis
MCF-7 cells and MCF-7/ADR cells were seeded onto 6-well culture plates at a
concentration of 1  105 cells/well. The apoptosis of cells exposed to Dox and Dox-
HBDL at a Dox concentration of 10 mM for 48 h was determined. After treatment, cells
were trypsinized, centrifuged, washed with PBS, and stained with FITC-labeled
Annexin V and propidium iodide following the manufacturer’s instructions. The
numbers of cells undergoing necrosis (positive for propidium iodide), early
apoptosis (positive for Annexin V), and late apoptosis (double-positive for Annexin V
and propidium iodide) were quantiﬁed using ﬂow cytometry. To study the induction
of JNK phosphorylation, MCF-7 and MCF-7/ADR cells were seeded at semiconﬂuent
concentrations on 12-mm coverslips in the wells of a 12-well plate. Cells were
incubated with free Dox (5 mM) or Dox-HBDL nanoparticles (5.0 mM Dox-equivalent)
for 24 h at 37 C in 5% CO2. After incubation with primary antibody, Alexa 647-
conjugated-secondary antibody was added. Immunoﬂuorescence was detected
and analyzed using CLSM. All experiments were repeated three times and repre-
sentative results are presented.
2.10. Statistical analysis
The data is presented as mean values with standard deviations (SD). Statistical
analysis was performed with one-way ANOVA followed by Tukey’s multiple com-
parison tests, and p < 0.05 was considered statistically signiﬁcant. The data were
processed and plotted in KaleidaGraph v4.1 (Synergy Software, Reading, PA).
3. Results and discussion
3.1. Uptake studies and cytotoxicity
Dox-encapsulated HBDL (Dox-HBDL) NPs were prepared by the
mixed phase method as previously reported [37]. A multidrug
resistant cancer cell line, MCF-7/ADR, which was engineered to
overexpress MGST1, was selected to evaluate the ability of Dox-
HBDL NPs to overcome drug resistance [39]. Immunoﬂuorescent
staining in Fig. 1A shows that MGST1 is expressed at much higher
levels in the MCF-7/ADR cells compared to normal MCF-7 cells. The
half maximal inhibitory concentration (IC50) of Dox was deter-
mined by MTT assays after incubation of free Dox or Dox-HBDL NPs
at equivalent Dox concentrations with both MCF-7 and MCF-7/ADR
cells for 72 h. Free Dox showed notable cytotoxicity to MCF-7 cells
at low concentrations (IC50 7.5 mM  1.8 mM) but was much lesscytotoxic to MCF-7/ADR cells (IC50 36.2 mM  3.2 mM). This
conﬁrmed that MGST1 overexpression confers robust resistance to
free Dox. Dox-HBDL NPs exhibited enhanced cytotoxicity compared
to free Dox treatment under identical conditions with an IC50 of
4.8 mM 1.0 mM in MCF-7 cells and an IC50 of 6.3 mM 1.4 mM in MCF-
7/ADR cells (Fig. 1B and C). As a control, empty HBDL NPs without
Dox were not cytotoxic to either MCF-7 or MCF-7/ADR cells after
72 h incubation (Supplemental Information, Fig. S2) indicating that
the cytotoxicity of Dox-HBDL is an effect of the nanoformulation of
the chemotherapeutic agent within the HBDL carriers. These ob-
servations show that Dox-HBDL NPs effectively overcome MGST1-
dependent drug resistance.
To investigate whether the effect of Dox-HBDL NPs was
dependent on changes in intracellular drug accumulation, cellular
uptake of free Dox or Dox-HBDL NPs in MCF-7 cells and MCF-7/
ADR cells was quantiﬁed at different time intervals from 1 h to
24 h. Free Dox or Dox-HBDL NPs in the culture medium was
incubated with either MCF-7 or MCF-7/ADR cells at an equivalent
dose of 1 mM Dox. The kinetics of drug accumulation was quanti-
tatively determined by ﬂow cytometry, and Fig. 2A illustrates the
intracellular accumulation of free Dox in MCF-7 or MCF-7/ADR
cells, respectively. The ﬂuorescence intensity of free Dox in MCF-
7/ADR cells (163  5) was signiﬁcantly lower than that seen in
MCF-7 cells (212  7) after incubation with free Dox for 24 h. The
decrease in intracellular drug concentrations could be a result of
the increased detoxiﬁcation capacity of the cells due to the MGST1
overexpression that contributes to drug resistance [39]. However,
when incubated with Dox-HBDL NPs the ﬂuorescence intensity in
MCF-7/ADR cells increased more rapidly than in MCF-7 cells
(Fig. 2B). Much higher ﬂuorescence intensities were observed in
MCF-7/ADR cells (82  4) compared to MCF-7 cells (61  2) after
incubation for the same period. These results indicate that Dox-
HBDL NPs might not be detoxiﬁed as quickly as free Dox by
MGST1, and the drug could be retained for a longer time in the
resistant cells after internalization. The enhanced cellular uptake
of Dox-HBDL NPs also contributes to the overcoming of the drug
resistance.
The mean ﬂuorescence intensities of MCF-7 cells and MCF-7/
ADR cells treated with free Dox were much higher than after in-
cubation with an equivalent dose of Dox-HBDL NPs for the same
period of time under the same conditions, and the trend increased
with longer culturing time. As shown in Fig. 2C, the cellular ﬂuo-
rescence intensities of MCF-7 and MCF-7/ADR cells treated with
free Dox were about 4 and 2 times higher, respectively, than the
intensities after Dox-HBDL NP treatment. It should be mentioned
that the ﬂuorescence intensity of Dox-HBDL NPs was not signiﬁ-
cantly different from that of free Dox at the same molar concen-
tration. The cellular uptake of Dox (free Dox or its equivalent in
nanoparticle form) was also investigated by confocal laser scanning
microscopy. Compared with the cells treated with free Dox, the red
ﬂuorescence intensity was much weaker in cells treated with Dox-
HBDL NPs (Fig. 2D). Furthermore, the red ﬂuorescence intensity in
the nuclei of the cells treated with Dox-HBDL NPs was also lower
compared to the nuclei of cells treatedwith free Dox (Fig. 2E). These
results indicate that cells apparently internalize the Dox-HBDL NPs
more slowly than free Dox, and this might be due to the difference
between endocytosis of the nanocarrier and the diffusion of a
small-molecule drug [37,41].
The above results demonstrated that delivery of Dox using NPs
couldefﬁciently increase the cellulardrugconcentration inMCF-7/ADR
cells comparedwith that inMCF-7cells andcould sensitizeMCF-7/ADR
cells to the drug and improve its cytotoxicity. However, it is interesting
to note that the drug uptake of Dox-HBDL NPs was signiﬁcantly lower
than free drug in both sensitive cells and resistant cells under the same
conditions, which means that the proﬁles of drug uptake are not fully
Fig. 3. (A) Effect of endocytic inhibitors or low temperature on accumulation of Dox-HBDL NPs in MCF-7/ADR cells. Cells were untreated (control) or pretreated with inhibitors for
30 min at 37 C prior to addition of Dox-HBDL NPs (1 mM). The ﬂuorescence signal was measured following incubation for 3 h at 37 C in all cases except the one labeled 4 C. Data
represent the mean  SD (n ¼ 3). *p < 0.05 and **p < 0.01 compared to control. (B) The role of macropinosomes, clathrin-coated pits, and caveolae in endocytosis of Dox-HBDL NPs
in MCF-7/ADR cells. Dox-HBDL micelle (red) co-localization with endocytic markers (green). High co-localization (yellow vesicles) was observed with dextran (macropinocytosis)
and transferrin (clathrin pathway), but no correlation with Cholera toxin B subunit (CTB) signal (caveolin pathway) was observed. Scale bar ¼ 20 mm. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Intracellular accumulation of Dox in MCF-7/ADR cells after treatment with Dox-HBDL micelles (A) and free Dox (B), respectively. Co-localization of Dox-HBDL micelles (red)
with lysosensor (lysosome marker, green), EEA1 (early endosome marker, green), ERtracker (endoplasmic reticulum marker, green), Mitotracker (mitochondria marker, green), and
TGN46 (Golgi apparatus marker, green) 3 h after the nanoparticle treatment shows that the particles are mostly delivered to the lysosomes, mitochondria, and endoplasmic re-
ticulum. Scale bar ¼ 20 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
X. Zeng et al. / Biomaterials 35 (2014) 1227e1239 1233equivalent to the drug effects. This suggests that there are additional
factors that contribute to the enhanced cytotoxicity of the NPs, for
example, endocytosis, distribution, MGST1 inhibition, enhanced
apoptosis, or altered molecular mechanisms of action.3.2. Mechanisms of endocytosis and confocal studies
Resistant and non-resistant cells were treated with Dox-HBDL
NPs to investigate the role of endocytosis in Dox uptake,
Table 1
Pearson’s coefﬁcients for Dox co-localization with markers of cytoplasmic
compartments.
EEA1 Lysosensor Mitotracker ERtracker TGN
Free Dox 0.11  0.21 0.63  0.14 0.19  0.16 0.05  0.19 0.14  0.13
Dox-HBDL 0.13  0.10 0.76  0.12 0.71  0.15 0.63  0.14 0.19  0.21
X. Zeng et al. / Biomaterials 35 (2014) 1227e12391234intracellular localization, and accumulation. Endocytosis is one of
the most important entry mechanisms for various extracellular
materials and is a primary mechanism for the uptake of NPs [41e
44]. Endocytosis is an energy-dependent mechanism and can be
inhibited at low temperatures (e.g., 4 C) [36,45]. As shown in
Fig. 3A, incubation of MCF-7/ADR cells with Dox-HBDL NPs at 4 C
for 3 h resulted in a 32.5% decrease in Dox accumulation compared
to cells incubated at 37 C. Inhibition of macropinocytosis and the
clathrin and caveolae pathways by exposing cells to their respective
inhibitors cytochalasin D, amiloride, and phenylarsine oxide for 3 h
resulted in signiﬁcant inhibition of Dox-HBDL NP transmigration
(Fig. 3A). Dox-HBDL NP (red) co-localization assays with endocyticFig. 5. MGST1 expression and intracellular glutathione (GSH) levels in MCF-7 cells and MC
5 mM for 24 h. (A) Representative ﬂow cytometric analyses of MGST1 expression. (B) Quantiﬁ
*p < 0.01, **p < 0.01, and ***p < 0.001 compared to control.markers (green) were studied by confocal imaging in vitro, and a
signiﬁcant amount of co-localization (yellow vesicles) was
observed with transferrin (a clathrin pathwaymarker), and dextran
(a macropinocytosis marker) but no correlation with the caveolin
signal was observed (Fig. 3B). We can conclude from these results
that the processes involved in translocation of Dox-HBDL NPs
across MCF-7/ADR cell membranes are energy-dependent and
include macropinocytosis and clathrin-mediated endocytosis. This
is in contrast to the diffusion-based translocation seen for free Dox
across MCF-7 cell membranes.
To conﬁrm that the red ﬂuorescence in Fig. 3B represents not
just that of released Dox from the HBDL NPs, a sample of the cells
was dosed with Dox-loaded and ﬂuorescently labeled (Dox-HBDL-
FL) nanocarriers that were synthesized as previously reported
[36,37]. Confocal microscopy showed the co-localization of the FL
and Dox channels (green and red) depicting the cellular internali-
zation of Dox-HBDL-FL NPs as a nanocarrier (Supplemental Infor-
mation, Fig. S4). These observations agree with our previous study
that showed that endocytic internalization was the mainF-7/ADR cells treated with Dox and Dox-HBDL nanoparticles at a Dox concentration of
cation of the ﬂow cytometry results. (C) A thiol assay was used to determine GSH levels.
Fig. 6. Mitochondrial function, oxidative stress, and lipid peroxidation of MCF-7 cells and MCF-7/ADR cells treated Dox and Dox-HBDL at a Dox concentration of 5 mM for 24 h. (A)
The mitochondrial membrane potential (Djm) of the cells was measured by ﬂow cytometry using the MitoDiIC kit. (B) Mitochondria-generated superoxide in the cells was
measured using the MitoSox assay. (C) Cellular ROS production was measured using the CellROX assay. (D) Lipid peroxidation in the cells was measured by the Bodipy assay.
**p < 0.01 and ***p < 0.001 compared to control.
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NPs have diameters of around 320 nm (Supplemental Information)
and are within the favorable size range for macropinocytosis and
clathrin-mediated endocytosis [36,37].
The energy dependence and uptake pathways of HBDL-DOX
transport in MCF-7 cells were also studied, and clear re-
ductions in the intracellular accumulation of Dox were observed
at 4 C and with inhibitors of macropinocytosis compared with
the control group (Supplemental Information, Fig. S5). However,
inhibitors of the clathrin pathway did not reduce the uptake of
Dox-HBDL signiﬁcantly. Furthermore, less transferrin signal was
detected in MCF-7 cells compared with resistant cells, and a faint
signal of co-localization of Dox-HBDL and transferrin was
observed in MCF-7 cells by confocal imaging (Supplemental In-
formation, Fig. S6). This is in contrast to the substantial amountof co-localization seen in MCF-7/ADR cells (Fig. 3B). We interpret
this to be due to the MGST1 overexpression. Clathrin binding by
fusion to GST has been reported to be associated with the as-
sembly of clathrin coats [46], and the higher levels of MGST1 in
MCF-7/ADR cells is suggested to promote assembly of clathrin
coats and to enhance the uptake of Dox-HBDL NPs. The data
indicate that not only the physicochemical properties of the NPs
but also cellular factors inﬂuenced the rate of Dox-HBDL uptake
across the plasma membrane.
3.3. Intracellular localization of Dox
To identify the intracellular distribution of Dox (red channel)
delivered by HBDL NPs, we performed co-localization assays with
EEA1, lysotracker, ERtracker, Mitotracker, and TGN as known
X. Zeng et al. / Biomaterials 35 (2014) 1227e12391236
X. Zeng et al. / Biomaterials 35 (2014) 1227e1239 1237markers (green channel) for early endosomes, lysosomes, the
endoplasmic reticulum, mitochondria, and Golgi apparatus,
respectively. As shown in Fig. 4, high co-localization (yellow) of
red ﬂuorescence with lysosensor, ERtracker, and Mitotracker
demonstrated that Dox-HBDL and its released Dox are primarily
transported to lysosomes, endoplasmic reticulum, and mito-
chondria following endocytosis of the carrier in MCF-7/ADR cells.
Conversely, a low co-localization signal was observed with EEA1
and TGN, and this indicates that the drug is not typically local-
ized within early endosomes or the Golgi network (Fig. S4 in the
Supplemental Information shows localization of free Dox after
6 h of cell incubation). Table 1 provides Pearson’s coefﬁcients for
each co-localization. These results show that free Dox signiﬁ-
cantly co-localized with lysosensor, but no Dox signal was
observed in early endosomes or the Golgi network and there was
no strong correlation with the endoplasmic reticulum or mito-
chondria. Free drug in the cytosol of the cells can be degraded by
lysosomes, but the encapsulated drugs can be slowly released
through either passive diffusion or degradation of the biode-
gradable polymers [47]. The sustained drug release from our
nanocarriers in cytoplasmic depots might be a contributive factor
to the improvement of chemotherapy outcome and sensitization
of resistant cells to drugs. However, further studies are needed to
elucidate the details of cellular degradation of the HBDL NPs and
its kinetics.
The mode of nanoparticle trafﬁcking through various subcellu-
lar compartments usually determines the path of drug distribution
[47], and our current results are in agreement with our previous
studies. This HBDL NP carrier has been shown to bypass early
endosomes and the Golgi network and to be routed to the lyso-
somal compartments following its internalization [36], and Dox-
HBDL NP-treated cultures showed diffuse ﬂuorescence
throughout the cytoplasm [37]. This is contrast to the free Dox-
treated cultures that exhibited high drug accumulation in the
nuclei of the cells (Fig. 4). The present study suggests that Dox-
HBDL NPs have a strong afﬁnity for speciﬁc cellular organelles,
and the unique capacity for these carriers to facilitate sustained
release of the drug payload from the speciﬁc compartments could
be highly advantageous for speciﬁc drug delivery applications. The
endoplasmic reticulum and mitochondria are the major sites of
MGST1 expression [48] and are also the main cellular localization
sites of the Dox delivered by HBDL carriers (Fig. 4).
3.4. Evaluation of MGST1 expression, glutathione levels, and
oxidative stress
To explore the interaction of Dox-HBDL and MGST1, the
protein expression level of MGST1 in the cells was determined
by ﬂow cytometry after treatment with Dox-HBDL. Fig. 5A shows
that Dox-HBDL clearly leads to decreased MGST1 levels, and the
decline is greater in MCF-7/ADR cells compared to MCF-7 cells
that have low endogenous levels of MGST1. We have further
shown that free Dox had less effect on MGST1 expression in both
cell lines relative to Dox-HBDL, and the lower activity of free Dox
most likely stems from the low levels of free Dox located in the
endoplasmic reticulum and the mitochondria. The inhibition ofFig. 7. Evaluation of the apoptosis mechanisms of breast cancer cells treated with PBS (contro
channel analyses of MCF-7 and MCF-7/ADR cells after dual staining with FITC-conjugated ann
48 h and stained with FITC-conjugated Annexin V (horizontal axis) and propidium iodide (ve
sorting protocols. (B) Comparison of the cell death rates of MCF-7 and MCF-7/ADR cells
equivalent) in the cell culture was 10 mM in all experiments. Data are shown as the mean  S
Dox in MCF-7/ADR cells. Cells were incubated with the equivalent of 5 mM free Dox or Dox-
using a confocal laser microscope system. The nuclei were stained with DAPI (blue). Scale bar
is referred to the web version of this article.)GST enzymes has been reported to result in the overcoming of
the drug resistance [48,49], and these observations suggest that
inhibition of MGST1 expression could account for the enhanced
drug activity in MCF-7/ADR cells treated with Dox-HBDL NPs.
GST enzymes are known to catalyze the conjugation of gluta-
thione (GSH) with xenobiotics, and GSH plays an important role
in protecting cells against damage from free radicals, oxidants,
and electrophiles [50]. The effects of Dox-HBDL NPs on GSH
levels were examined using the ThioGlo-1 assay. As shown in
Fig. 5C, the GSH level in MCF-7/ADR cells decreased after a 24-
h treatment with Dox-HBDL presumably because more GSH is
consumed as more free radicals, lipid peroxides, and oxidants are
formed. Lower GSH levels are expected during cell toxicity (for
example by mitochondrial damage caused by Dox-HBDL), and
not from alteration of MGST1 per se, as shown by Johansson
et al. [39].
We further assessed mitochondrial function, the production of
reactive oxygen species (ROS), and lipid peroxidation to investi-
gate the cytotoxic effects of free Dox and Dox-HBDL NPs. A
MitoDiIc assay [40] showed that Dox-HBDL NPs induced signiﬁ-
cant dissipation of the mitochondrial membrane potential in both
cell lines, but free Dox only triggered mitochondrial dysfunction in
MCF-7 cells (Fig. 6A). Moreover, Dox-HBDL treatment resulted in
signiﬁcant production of mitochondrial ROS, cellular ROS, and
lipid peroxides as shown in Fig. 6B, C, and D, respectively. In
contrast, free Dox treatment induced comparable effects on
cellular ROS and lipid peroxides only in MCF-7 cells and not in
MCF-7/ADR cells. Mitochondria are the major source of ROS gen-
eration in the cell [51]. Overproduction ROS and the accumulation
of ROS in cells causes damage to lipids, proteins, and DNA and
leads to mitochondrial membrane permeabilization that further
initiates apoptosis [51,52]. The present study shows that Dox-
HBDL increases ROS production and lipid peroxidation as well as
induces dissipation of the mitochondrial membrane potential in
MCF-7/ADR cells more efﬁciently than free Dox. In contrast to free
Dox that mainly accumulates in the nuclei, we show here that the
mitochondria is the major target and plays a central role in how
Dox-HBDL is able to overcome drug resistance. As MGST1 is
known to protect cells from oxidative stress induced cell death
[53], the lowered protection against Dox-HBDL is somewhat
counterintuitive. We suggest that the lowering of MGST1 expres-
sion together with the more severe oxidative stress induced
overcomes the protective ability.
3.5. Induction of apoptosis and JNK activation
Because Dox-HBDL NPs induced the dissipation of the mito-
chondrial membrane potential, we further studied the apoptosis
and necrosis that is induced by Dox-HBDL NPs. It is well known that
mitochondria are involved in the regulation of apoptosis [51], and
the loss of the mitochondrial membrane potential can trigger the
release of apoptogenic factors from mitochondria into the cytosol
that further initiates the sequential death of the cell [52] Fig. 7
shows that MCF-7 cells treated with Dox suffered signiﬁcant
levels of apoptosis and necrosis. Dox-HBDL NPs enhance the sus-
ceptibility of both cancer cell lines to Dox and induce signiﬁcantlyl), free Dox, and Dox-HBDL micelles. (A) Representative dot plots showing ﬂuorescence
exin V and propidium iodide. The cells were treated with free Dox or Dox-HBDL NPs for
rtical axis) before being analyzed using ﬂow cytometry and ﬂuorescence-activated cell
exposed to free Dox and Dox-HBDL NPs for 48 h. The concentration of Dox (free or
D (n ¼ 3). (C) Dox-HBDL micelles induced signiﬁcant activation of JNK compared to free
HBDL NPs for 24 h. Immunoﬂuorescence of phosphorylated JNK (p-JNK) was detected
¼ 20 mm. (For interpretation of the references to colour in this ﬁgure legend, the reader
X. Zeng et al. / Biomaterials 35 (2014) 1227e12391238more apoptosis in the cells. Apoptosis was induced in 27.1% and
43.4% of the MCF-7 cells after treatment with Dox and Dox-HBDL
NPs, respectively. Treatment with Dox had a slight inﬂuence on
the MCF-7/ADR cells and induced apoptosis in 14% of the cells.
Treatment of MCF-7/ADR cells with Dox-HBDL NPs induced ne-
crosis and apoptosis in 8.4% and 31.3% of the cells, respectively. The
enhanced apoptotic effects of Dox-HBDL NPs correlated linearly
with the effects of the HBDL NP on the mitochondrial function in
resistant cells shown in Fig. 6. This implies that mitochondria-
mediated apoptosis plays a central role in the cell death induced
by Dox-HBDL NPs.
Jun-terminal kinase (JNK), which is responsible for the stress
response through apoptosis, has been reported to be maintained at
a low level because GST functions as an endogenous negative reg-
ulatory switch for this kinase [54,55]. Based on the MCF-7/ADR cell
model in which MGST1 is overexpressed and Dox-HBDL NPs
decrease the levels of MGST1, we hypothesized that the JNK-
mediated pathway of apoptosis would contribute to the cytotox-
icity of Dox-HBDL NPs in MCF-7/ADR cells. JNK activation is
mediated by phosphorylation at threonine 183 and tyrosine 185 in
the conserved TPY tripeptidemotif in the kinase domain. Therefore,
the levels of phosphorylated JNK at threonine 183 and tyrosine 185
were analyzed after treatment of cells with Dox and Dox-HBDL NPs.
Confocal microscopy showed that JNK had translocated into the
nucleus, which is characteristic for JNK activation. As shown in
Fig. 7C, much stronger JNK ﬂuorescence was detected in the nuclei
of MCF-7/ADR cells treated with Dox-HBDL NPs compared to free
Dox suggesting that Dox-HBDL NPs could activate the JNK pathway
to a higher degree. This in turn contributes to the enhancement of
apoptosis of MCF-7/ADR cells and the ability to overcome drug
resistance and suggests that JNK might be employed as a potential
therapeutic target for the use of nanocarriers against drug
resistance.
Both free Dox and Dox-HBDL NPs activated JNK in MCF-7 cells
because translocation of phosphorylated JNK to the nuclei could be
observed within 24 h at equivalent Dox concentrations of 5 mM
(Supplemental Information, Fig. S7). Therefore, it is concluded that
JNK activation contributes to the apoptosis of MCF-7 cells treated by
both free drug and Dox-HBDL, and the enhanced apoptosis of the
MCF-7/ADR cells by Dox-HBDL is most probably due to the highly
activated JNK. In control experiments, empty HBDL NPs without
Dox did not have any signiﬁcant effect on the cell functions studied
in either MCF-7 or MCF-7/ADR cells. This indicates that the effects
of Dox-HBDL NPs are not due to the presence of the polymer-based
carriers.
4. Conclusions
Drug resistance remains one of the most challenging problems
to overcome in cancer treatment. The use of nanotechnology for
drug delivery is a promising strategy for combating drug resistance,
but understanding how the nanocarriers affect drug delivery re-
mains a major obstacle to their potential applications. Here, we
demonstrate that drug resistance in an MGST1-overexpressing
human breast cancer cell line can be overcome by treatment with
Dox encapsulated within our polyester-based DDS. Although Dox-
HBDL NPs achieved enhanced drug accumulation in drug-
resistant cancer cells compared to drug-sensitive cells, much less
drug from the NPs was delivered in both the resistant and sensitive
cells compared to treatment with free drug. Our data show that the
uptake of Dox-HBDL is via an active endocytic transport mechanism
involving macropinocytosis and clathrin-mediated pathways and
the triggering of multistep processes that are distinct from the
uptake of free Dox. This is strongly supported by our results
showing 1) the accumulation of Dox-HBDL NPs in lysosomes,endoplasmic reticulum, and mitochondria and a lack of accumu-
lation in nuclei; 2) inhibition of the GST detoxiﬁcation system that
increases the amount of the drug available to react with its target
molecules; 3) dissipation of the mitochondrial membrane potential
and an increase in ROS levels in the cytoplasm; 4) activation of pro-
apoptotic JNK signaling in drug-resistant cells; 5) a decrease in drug
degradation within lysosome vesicles; and 6) an overall increase in
apoptosis and cell death. In summary, our ﬁndings strongly suggest
that drug resistance in cancer cells can be signiﬁcantly circum-
vented through the use of HBDL NPs that can deliver drugs to
speciﬁc organelles while minimizing the intracellular concentra-
tions of the drugs. This work is signiﬁcant in the ﬁeld of nano-
medicine research because it provides understanding of the
nanomaterial’s modulation of chemotherapeutic mechanisms of
action and has important implications for rational design of DDS’s
to improve the efﬁcacy of nuclear-acting chemotherapeutics
against drug-resistant cancers.
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